ROCKLAND IMMUNOCHEMICALS, INC. — Department of Health and Human Services SBIR Phase I: NHLBI

Description

DESCRIPTION provided by applicant Hemoglobinopathies are the most common monogenic diseases with approximately of the worldandapos s population being carriers Sickle cell disease SCD and thalassemia are primarily hemoglobin disorders The current SCD diagnostic methods require expensive equipment and are performed by highly trained laboratory technologists Presently there are no simple and inexpensive screening tests that can differentiate patients with sickle cell trait HbAS from sickle cell disease conditions HbSS HbSC and HbS ss thalassemias The goal of this project is to develop antibody based lateral flow POC device that will allow efficiently inexpensively and rapidly diagnose a patient with SCD In Phase I hemoglobin isoform specific antibodies will be developed and lateral flow POC device prototypes will be formulated In Phase II POC device will be optimized produced in a large scale and undergo extensive field hospital tests PUBLIC HEALTH RELEVANCE Sickle cell disease SDC is the most common genetic disorder As a result of this project antibody based lateral flow Point of Care device will be developed allowing efficiently inexpensively and rapidly diagnose sickle cell disease in infants and young children in low income and low resource settings End of Abstract